(PHR) Q3 2026 earnings review
Profitability Inflection Point Reached
Phreesia delivered a watershed quarter, swinging to positive GAAP Net Income ($4.3M) for the first time, compared to a $14.4M loss a year ago. The 'growth at all costs' era is officially over; the company is now a cash-generating engine. While organic revenue growth decelerated slightly to 13%, Adjusted EBITDA nearly tripled to $29.1M. Management introduced FY27 guidance projecting 14-16% growth, bolstered by the $160M acquisition of AccessOne.
🐂 Bull Case
Adjusted EBITDA margin hit 24% in the quarter (up from 9% a year ago). Sales & Marketing expenses actually dropped $6M YoY while revenue grew, proving the platform has operating leverage.
The $160M purchase of AccessOne (patient financing) expands the Total Addressable Market (TAM) significantly. It adds ~$35M in annualized revenue and is immediately accretive to EBITDA.
🐻 Bear Case
Total revenue growth slowed to 13% YoY, down from 15% in Q1/Q2. The FY26 revenue guidance bump ($479M midpoint) is driven entirely by the $7.5M contribution from AccessOne, implying core business growth is flattening.
The payment take rate slid to 2.7%, down from 2.9% earlier in the year. Management is trading margin for volume to encourage 'payment facilitator' adoption, but this caps upside in the payments segment.
⚖️ Verdict: 🟢
Bullish. The swing to GAAP profitability and positive Free Cash Flow validates the business model. While organic top-line growth is moderating, the disciplined cost control and strategic M&A provide a clear path to shareholder value.
Key Themes
Operating Leverage Breakthrough
Accelerating. Phreesia has successfully decoupled revenue growth from expense growth. While revenue grew 13%, Total Operating Expenses (Adjusted) fell by roughly $7M. Sales & Marketing expenses dropped nearly 20% YoY. This drove Adjusted EBITDA to $29.1M, crushing the $9.8M result from a year ago.
Payment Take Rate Pressure
Decelerating. The payment take rate (fees earned as % of volume) dropped to 2.7%, a new low compared to the historical ~2.9% range. Management attributes this to a strategy of offering flexible pricing to drive volume, but it creates a headwind. Payment Processing Fees revenue (+11%) trailed overall revenue growth (+13%).
AccessOne Strategic Acquisition
The acquisition of AccessOne closed Nov 12 (post-quarter). It adds patient financing capabilities, addressing the 'affordability' macro trend. Financial impact: adds ~$7.5M revenue to Q4 FY26. It was funded via a $110M bridge loan, introducing leverage to the balance sheet, but management expects to refinance.
Organic Growth Deceleration
Decelerating. Excluding the acquisition, the implied organic growth for FY26 is stabilizing at best. The company maintained the organic portion of its guidance rather than raising it, despite the strong profit beat. The 13% growth in Q3 is the slowest in the last 5 quarters.
Network Solutions Strength
Stable. Network Solutions (Life Sciences marketing) grew 14% YoY, outpacing other segments. This high-margin segment is critical for profitability. The growth was driven by strong campaign pacing, though management noted the inherent lumpiness of this revenue stream.
Other KPIs
Reversing. For the first time, Phreesia posted positive GAAP Net Income, a massive turnaround from the -$14.4M loss in the prior year period. This quality of earnings improvement reduces reliance on non-GAAP adjustments.
Accelerating. Up from $1.6M in the prior year. The company has now stacked multiple quarters of positive cash flow, ending the quarter with $106.4M in cash (pre-acquisition spend).
Stable. Clients grew 7% YoY. While steady, client addition velocity is moderate. Revenue per client grew 6% YoY to $26,622, indicating successful cross-selling.
Guidance
Stable. The previous range was $472M-$482M. The new midpoint ($480M) is $3M higher than the old midpoint ($477M). However, the company explicitly states this includes ~$7.5M from AccessOne. This implies the organic revenue forecast was actually lowered slightly at the midpoint.
Accelerating. Raised significantly from previous $87M-$92M. Even excluding AccessOne contributions, the organic margin expansion is ahead of schedule.
Accelerating. Implies 14-16% growth over FY26. AccessOne is expected to contribute ~6.5% of this total. This suggests organic growth is expected to remain in the high single digits or low double digits.
Accelerating. Implies continued margin expansion. Midpoint ($130M) represents ~30% growth over FY26 guidance.
Key Questions
Organic Revenue Health
The FY26 revenue guide bump appears to be entirely driven by the $7.5M AccessOne contribution, implying a slight organic trim. Is this conservatism, or are you seeing elongation in sales cycles for the core product?
Take Rate Floor
Take rate compressed to 2.7% this quarter. Is this the new normal, or do you expect further compression as you aggressively price to gain payment facilitator volume?
AccessOne Integration & Debt
You funded AccessOne with a $110M bridge loan. What is the timeline and target structure for the permanent financing, and how does this interest expense impact your path to GAAP profitability in FY27?
Sales & Marketing Sustainability
S&M expense is down significantly YoY. Can you sustain 14-16% revenue growth in FY27 with this leaner S&M structure, or will investment need to ramp back up?